Citadel Advisors’s Lipella Pharmaceuticals LIPO Stock Holding History

Citadel Advisors’s Portfolio LIPO Stock Details LIPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,759	Closed	-$15.1K	–	14939
2024 Q1	$15.1K	Buy	+2,759	New	+$20.5K	﹤0.01%	13204
2023 Q1	–	Sell	-1,564	Closed	-$39.8K	–	15149
2022 Q4	$39.8K	Buy	+1,564	New	+$47.7K	﹤0.01%	12425

Other funds holding LIPO

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's LIPO Position: Q2 2024 in Review

Citadel Advisors sold out of Lipella Pharmaceuticals (LIPO) in Q2 2024, closing a stake of 2,759 shares — an estimated $15.1K sold.

Citadel Advisors first reported a position in LIPO in Q4 2022 and held it in 2 quarters. The position peaked at $39.8K in Q4 2022. 7 funds tracked by Wall St. Rank hold LIPO as of Q2 2024.

Citadel Advisors reported no remaining Lipella Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Citadel Advisors sold 2,759 Lipella Pharmaceuticals shares in Q2 2024, an estimated $15.1K.
Citadel Advisors first reported a position in Lipella Pharmaceuticals in Q4 2022 and held it in 2 quarters.
Citadel Advisors's Lipella Pharmaceuticals position peaked at $39.8K in Q4 2022.
7 funds tracked by Wall St. Rank held Lipella Pharmaceuticals as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.